Form 4: Plus Therapeutics CFO Acquires Shares and Warrants

Andrew Sims, CFO of Plus Therapeutics, reports acquisition of common stock and warrants.

Summary

• On May 8, 2024, Andrew Sims, the Chief Financial Officer of Plus Therapeutics, acquired 4,902 shares of common stock at a price of $2.04 per share.
• Following this transaction, Sims directly owns 5,717 shares of common stock.
• On the same date, Sims also acquired 9,804 warrants with an exercise price of $1.79.
• Half of the warrants (4,902) are Series A warrants expiring on May 8, 2029, and the other half (4,902) are Series B warrants expiring one year after the effectiveness of a registration statement covering the resale of the underlying common stock.
• After the transaction, Sims directly owns 9,804 warrants.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of insider trading activity. The CFO's purchase could be seen as a positive signal, but it's not definitive.

Positives

• The CFO's acquisition of shares and warrants could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like the CFO, trade in their company's securities. These filings provide transparency to the market.

Stakeholder Impact

• The CFO's stock purchase could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Form 4, Beneficial Ownership, Andrew Sims, Plus Therapeutics, PSTV, CFO, Common Stock, Warrants, Acquisition